Miscellaneous Drugs

Question 1

Imatinib (Gleevac)

Answer 1

TK inhibitor(Abl) , first line therapy for CML also used for GIST

Question 2

Gefitinib (Iressa) and Erlotinib (Tarceva)

Answer 2

TK inhibitor (EFGR), non small cell lung cancer

Question 3

Nilotinib (Tasigna)

Answer 3

TK inhibitor (Abl), imatinib resistant CML

Question 4

Dasatinib (Sprycel)

Answer 4

TK inhibitor (abl and src), imatinib resistant CML

Question 5

Rituximab (Rituxin)

Answer 5

Monoclonal Ab to CD20 B-Cell marker induce apop, activate comp, or CMI. Non-hodgkins Lymphomas (follicular t(14;18))

Question 6

Trastuzumab (Herceptin)

Answer 6

Mono Ab, HER2/neu (ErbB2) antibody, HER2/neu expressing metastatic breast cancer

Question 7

Cetuximab (erbitux)

Answer 7

Mono Ab, EGFR1 (ErbB1), EGFR positive metastatic colorectal cancer

Question 8

ipilimumab (yervoy)

Answer 8

human mono Ab, CTL antigen 4 inhibitor, melanoma

Question 9

vermurafenib (zelboraf) and dabrafenib (tafiniar)

Answer 9

ser/threo kinase inhibitor (BRAF kinase), unresectable stage 3 or 4 metastatic melanomas with BRAF mutations

Question 10

trametinib (mekinist)

Answer 10

inhibits MEK, unresectable stage 3 or 4 metastatic melanomas with BRAF mutations

Question 11

Hydroxyurea (Hydrea)

Answer 11

inhibits ribonucleoside diphosphate reductase, CML (replaced by imatinib) polycythemia vera, essential thrombocythemia, and sickle cell (increases Hb-F)

Question 12

Retinoids

Answer 12

ATRA induces terminal differentiation used for APL

Question 13

Arsenic Trioxide

Answer 13

relapsed APL

Question 14

Thalidomide (Thalomid)

Answer 14

mutiple myeloma and myelodysplastic syndromes

Question 15

Interferons

Answer 15

Hairy Cell Leukemia, CML, and AIDs related Kaposi sarcoma.